睿知中国疾病研究地图
候选清单0

正在招募多发性骨髓瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验。牵头方不是本站收录的医院;本站收录的 19 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 19

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心首都医科大学附属北京朝阳医院Beijing Chao-Yang Hospital北京医院页面
  2. 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
  3. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  4. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  5. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  6. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  7. 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
  8. 研究中心福建医科大学附属协和医院Fujian Medical University Union Hospital福州医院页面
  9. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  10. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  11. 研究中心中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面
  12. 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
  13. 研究中心北京大学人民医院Peking University People's Hospital北京医院页面
  14. 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
  15. 研究中心青岛市市立医院Qingdao Municipal Hospital青岛医院页面
  16. 研究中心河北医科大学第二医院Second Hospital of Hebei Medical University石家庄医院页面
  17. 研究中心天津医科大学总医院Tianjin Medical University General Hospital天津医院页面
  18. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  19. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT04973605,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory

    入选标准第 8 条

  3. In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.

    入选标准第 5 条

    Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD

    入选标准第 7 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

    入选标准第 1 条

  5. Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)

    入选标准第 10 条

    Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions

    入选标准第 11 条

    Absolute neutrophil count (ANC) ≥ 1000/mm\^3 within 7 days before first dose of study treatment

    入选标准第 12 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)

    入选标准第 13 条

  6. Known infection with human immunodeficiency virus (HIV)

    排除标准第 18 条

    Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:

    排除标准第 19 条

    Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.

    排除标准第 20 条

    Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04973605,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  2. A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)
  3. Measurable disease defined as:
  4. Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.
  5. In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
  6. Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
  7. Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD
  8. Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory
  9. Adequate organ function defined as:
  10. Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)
  11. Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions
  12. Absolute neutrophil count (ANC) ≥ 1000/mm\^3 within 7 days before first dose of study treatment
  13. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)

排除标准:Exclusion Criteria:

  1. Participant has any of the following conditions:
  2. Non secretory MM (Serum free light chains < 10 mg/dL)
  3. Solitary plasmacytoma
  4. Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or > 2.0 x 109/L circulating plasma cells by standard differential)
  5. Waldenström macroglobulinemia (WM)
  6. Amyloidosis.
  7. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
  8. Chronic respiratory disease that requires continuous oxygen
  9. Significant cardiovascular disease, including but not limited to:
  10. Myocardial infarction ≤ 6 months before screening
  11. Ejection fraction ≤ 50%
  12. Unstable angina≤ 3 months before screening
  13. New York Heart Association Class III or IV congestive heart failure
  14. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
  15. Heart rate-corrected QT interval > 480 milliseconds based on Fridericia's formula
  16. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
  17. Uncontrolled hypertension at screening, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
  18. Known infection with human immunodeficiency virus (HIV)
  19. Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:
  20. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.
  21. Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).

引自 ClinicalTrials.gov, NCT04973605, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04973605,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT04973605